HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
HCW Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
HCW Biologics Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q3 25 | Q2 25 | Q1 25 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $121.73K | $230.00K | – | – | – | – | – | 100.0% | – |
| Licensed IP [Member] | $0 | $6.30M | – | – | – | – | – | 0.0% | – |
| Development Supply Materials | – | – | $15.61K | $6.55K | – | $426.42K | $618.85K | – | – |
| Clinical Materials | – | – | $15.61K | – | – | $500.00K | – | – | – |
| Ancillary Service [Member] | – | $13.00K | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of HCW Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.